Breaking News

Glaxo to Pay $488.7 Million Fine to End China Corruption Probe
Tweet TWEET

Santhera Pharmaceuticals Holding AG : Santhera Explores Strategic Options; Updates Financial Calendar

  Santhera Pharmaceuticals Holding AG : Santhera Explores Strategic Options;
                          Updates Financial Calendar

Santhera Pharmaceuticals Holding AG / Santhera Explores Strategic Options;
Updates Financial Calendar . Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.



Liestal, Switzerland, February28, 2013 - Santhera Pharmaceuticals (SIX:SANN)
announced today that following the voluntary withdrawal of Catena^® from the
Canadian market and the earlier negative decision of the Committee for
Medicinal Products for Human Use (CHMP) on the Market Authorization
Application for Raxone^® in Leber's Hereditary Optic Neuropathy (LHON), the
Board has decided to consider strategic options including product licensing
for Raxone^® in LHON and the possibility of a merger or acquisition. Santhera
has already received expressions of interest from third parties and has
retained Piper Jaffray Limitedto assist the Company in this process.

The publication of the financial results for 2012 will be postponed and,
together with the financial outlook for 2013, will now be provided within the
timelines required by the SIX regulations. Accordingly, the Company will
therefore postpone the Annual Shareholders' Meeting previously planned for
April22, 2013.

Shareholders should note that whilst the Board believes that it is in the best
interest of shareholders to explore these options and take the steps
described, there can be no guarantee that any transaction can be consummated.

                                    * * *

About Santhera

Santhera Pharmaceuticals (SIX:SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan neuromuscular and
mitochondrial diseases, areas of high unmet medical need with no current
therapies. For further information, please visit www.santhera.com.

For further information, contact

Thomas Meier, Chief Executive Officer

Phone: +41 61 906 89 64

thomas.meier@santhera.com

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from
those expressed or implied by such statements. Readers should therefore not
place undue reliance on these statements, particularly not in connection with
any contract or investment decision. The Company disclaims any obligation to
update these forward-looking statements.

News release

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
HUG#1681770

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;
 
Press spacebar to pause and continue. Press esc to stop.